A study by researchers at the UCLA Jonsson Comprehensive Cancer Center has identified a possible new drug that could help prevent cognitive decline in people who undergo radiation therapy for brain tumors. The researchers found when the drug was given to mice 24 hours after the animals were exposed to a dose of radiation, it completely prevented cognitive decline from occurring, and that it did not reduce the efficacy of the radiation treatment.
This experiment represents one of a very few instances in which a drug reduced cognitive decline in animals after radiation treatment.
The drug, NSPP, was identified in 2019 by scientists at the UCLA Center for Medical Countermeasures against Radiation.
Aside from surgery, radiation therapy is one of the most effective treatments for people with brain cancer or other cancers that have spread to the brain. Because more people with brain cancer are now surviving longer, more people are experiencing long-term side effects from the treatment.
Those side effects, like memory loss and difficulty with learning new things, can occur months or years after exposure to radiation. That can be particularly problematic for children and young adults who survive cancer, because their brains are still developing; their cognitive function can decline by as much as one to two IQ points per year over the course of their adulthood. Current treatments don't offer a way to avoid that result, other than when doctors can take steps to keep radiation away from critical structures in the brain during treatment.
NSPP had already been shown to prevent acute radiation syndrome in mice. Using normal mouse brains and glioblastoma tumor cells derived from patients, the researchers tested whether the drug could also affect neural stem cells and progenitor cells -- types of cells that can repair tissue damage in the brain -- without affecting tumor cells. To assess cognitive function in mice, the team used three behavioral tests: a novel object test, an object-in-place test and a contextual learning test. The study found NSPP was not toxic to normal cells and did not interfere with the growth-delaying effects of radiation in tumor cells.
The study provides evidence that NSPP has the potential to help prevent cognitive decline in people who undergo radiation for the treatment of a brain tumor, without taking away from the efficacy of the radiation treatment.
The study's senior author is Dr. Frank Pajonk, a UCLA professor of radiation oncology and a member of the UCLA Jonsson Comprehensive Cancer Center. The first author is Kruttika Bhat, a postdoctoral scholar at the David Geffen School of Medicine at UCLA, and the other authors are Paul Medina, Ling He, Mohammad Saki, Angeliki Ioannidis, Nhan Nguyen, Sirajbir Sodhi, David Sung, Clara Magyar, Dr. Linda Liau and Dr. Harley Kornblum, all of UCLA.
Pajonk and his colleagues are part of the National Institutes of Health Brain Specialized Programs of Research Excellence, or SPORE, at UCLA, which is dedicated to advancing the prevention, detection and treatment of brain tumors.
The study was published in the journal of Neuro-Oncology.
The research was supported by the National Cancer Institute and the National Institute of Allergies and Infectious Diseases.
The UCLA Jonsson Comprehensive Cancer Center has more than 500 researchers and clinicians engaged in cancer research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the UCLA Jonsson Comprehensive Cancer Center is dedicated to promoting research and translating basic science into leading-edge clinical studies.